Sweden's Apotea Q3 net revenue rises 12.5% on prescription products growth

By Reuters News


Overview

  • Sweden online pharmacy's Q3 net revenue rose 12.5% yr/yr to SEK 1.99 bln

  • Adjusted EBIT for Q3 increased, with margin improving to 5.4%

  • Growth driven by prescription products and improved customer offering


Outlook

  • Company highlights prescription products as a key driver for future growth

  • Company expands same-day delivery to 3.7 mln people, aiming to enhance customer experience


Result Drivers

  • PRESCRIPTION PRODUCTS - Co said Q3 growth was driven by prescription products, with improved customer offering

  • NEW INITIATIVES - Co said it launched new initiatives to simplify shopping experience

  • SAME-DAY DELIVERY - Co said expanded same-day delivery to 3.7 mln people since September


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Revenue

SEK 1.99 bln

Q3 Net Income

SEK 81.80 mln

Q3 Cash Flow from Operating Activities

SEK 25.80 mln

Q3 EBIT

SEK 107.40 mln

Q3 EBIT Margin

5.40%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the drug retailers peer group is "buy"

  • Wall Street's median 12-month price target for Apotea AB (publ) is SEK92.50, about 3.2% below its November 4 closing price of SEK95.60

  • The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 23 three months ago


Reuters Recommended Reads

  • Nov 4 - Sweden's Rugvista Q3 net revenue rises on high order volume

  • Nov 3 - Online fashion retailer Boozt Q3 revenue rises on wider assortment

  • Nov 3 - Zalando Q3 revenue slightly beats estimates on B2B expansion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.